Jiangsu Hengrui Pharmaceuticals announcement, its subsidiary Tianjin Hengrui Pharmaceuticals received the Fluorine [18F] Flumazenil Injection "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration, allowing the clinical trial of positron emission tomography imaging of neuropathic inflammation plaque density formed by β-amyloid protein aggregation in the brains of adult patients with Alzheimer's disease or other causes of cognitive impairment. The drug has accrued approximately 22.88 million yuan in research and development investment.